Ameriprise
NUVB icon

Ameriprise’s Nuvation Bio NUVB Stock Holding History

Ameriprise’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,120
Closed -$306K – 4177
2025
Q4 		$306K Buy
34,120
+20
+0.1% +$124 ﹤0.01% 3800
2025
Q3 		$126K Buy
+34,100
New +$92.9K ﹤0.01% 3957
2024
Q3 		– Sell
-234,030
Closed -$683K – 3984
2024
Q2 		$683K Hold
234,030
– – ﹤0.01% 3328
2024
Q1 		$852K Buy
234,030
+159,802
+215% +$307K ﹤0.01% 3230
2023
Q4 		$112K Buy
74,228
+26,284
+55% +$33.8K ﹤0.01% 3804
2023
Q3 		$64.2K Buy
47,944
+24,524
+105% +$40.8K ﹤0.01% 3826
2023
Q2 		$42.2K Buy
+23,420
New +$39.8K ﹤0.01% 3871
2022
Q1 		– Sell
-727,956
Closed -$6.19M – 3999
2021
Q4 		$6.19M Buy
727,956
+120
+0% +$1.1K ﹤0.01% 2318
2021
Q3 		$7.24M Hold
727,836
– – ﹤0.01% 2118
2021
Q2 		$6.78M Hold
727,836
– – ﹤0.01% 2235
2021
Q1 		$7.61M Buy
+727,836
New +$8.14M ﹤0.01% 2089

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise's NUVB Position: Q1 2026 in Review

Ameriprise sold out of Nuvation Bio (NUVB) in Q1 2026, closing a stake of 34,120 shares — an estimated $306K sold.

Ameriprise first reported a position in NUVB in Q1 2021 and held it in 11 quarters. The position peaked at $7.61M in Q1 2021. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Ameriprise reported no remaining Nuvation Bio position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 34,120 Nuvation Bio shares in Q1 2026, an estimated $306K.
  • Ameriprise first reported a position in Nuvation Bio in Q1 2021 and held it in 11 quarters.
  • Ameriprise's Nuvation Bio position peaked at $7.61M in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.